Health Care [ 5/12 ] | Biotechnology [ 39/73 ]
NYSE MKT | Common Stock
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds.
It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.
The company is headquartered in Toronto, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 1, 25 | -1.46 Decreased by -7.20 K% | -0.02 Decreased by -5.79 K% |
| Mar 31, 25 | -1.46 Decreased by -4.35 K% | -1.23 Decreased by -18.70% |
| Feb 11, 25 | -0.53 Decreased by -488.89% | -0.03 Decreased by -1.92 K% |
| Nov 13, 24 | -2.86 Decreased by -5.62 K% | -0.02 Decreased by -11.43 K% |
| Aug 8, 24 | -0.02 Increased by +71.43% | -0.02 |
| Jun 25, 24 | -0.03 Increased by +53.14% | -0.03 Decreased by -9.33% |
| Feb 14, 24 | -0.09 Decreased by -50.00% | -0.04 Decreased by -125.00% |
| Nov 13, 23 | -0.05 Increased by +16.67% | -0.05 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -24.61 M Decreased by -66.03% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -30.58 M Decreased by -43.25% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -10.54 M Increased by +65.24% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -57.19 M Decreased by -381.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -14.82 M Decreased by -19.79% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -21.35 M Decreased by -55.58% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -30.33 M Decreased by -182.35% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -11.89 M Decreased by -19.22% | Decreased by N/A% Decreased by N/A% |